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Abstract
Differently from the antiapoptotic action most commonly assigned to peroxisome proliferators (PPs), we demonstrated that
some of them, clofibrate (CF) in particular, display clearcut apoptogenic properties on rat hepatoma cell lines. We and
others could confirm that CF as well as various other PPs can induce apoptosis in a variety of cells, including human liver,
breast and lung cancer cell lines. The present study was aimed at investigating the cytotoxic action of CF on a neoplastic
line of different origin, the human T leukemia Jurkat cells. We observed that CF rapidly triggers an extensive and
morphologically typical apoptotic process on Jurkat cells, though not in primary T cells, which is completely prevented by
the polycaspase inhibitor zVADfmk. Gene silencing studies demonstrated that CF-induced apoptosis in Jurkat cells is
partially dependent on activation of caspase 2. Looking for a possible trigger of caspase 2 activation, we observed increased
levels of phosphorylated eIF2a and JNK in CF-treated cells. Moreover, intracellular Ca2+ homeostasis was perturbed.
Together, these findings are suggestive for the occurrence of ER stress, an event that is known to have the potential to
activate caspase 2. The present observations demonstrate that CF induces in Jurkat cells a very fast and extensive apoptosis,
that involves induction of ER stress and activation of caspases 2 and 3. Since apoptosis in Jurkat cells occurs at
pharmacologically relevant concentrations of CF, the present findings encourage further in depth analysis in order to work
out the potential implications of CF cytotoxcity on leukemic cells.
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Introduction
Clofibrate (CF) and other fibrate derivatives have long been
used as hypolipidemic drugs [1]. These compounds are part of
a largely heterogeneous class of chemicals known as peroxisome
proliferators (PPs). Their mechanism of action typically requires
binding to heterodimeric nuclear receptors in which a monomer of
RXR combines with a monomer of PP-activated receptor (PPAR).
Three different PPAR subfamilies (a, b/d, and c) have been
described [2], PPARa being particularly involved in fibrate-
activated signal transduction.
PPs have been shown to behave as hepatocarcinogens in rodents
[3]. Indeed, when administered to rats and mice they induce
peroxisome proliferation, hepatomegaly, and hepatocarcinogen-
esis [4,5]. By contrast, these effects cannot be observed in
monkeys, pigs and humans [6,7,8]. PPs are considered non-
genotoxic carcinogens, their oncogenicity apparently deriving
from both the oxidative response consequent to peroxisome
proliferation and their ability to interfere with the regulation of cell
proliferation and death [8,9]. PPARa appears mainly in charge of
these activities. Indeed, long term PPs administration does not
result in hepatocarcinogenesis in PPARa-null mice [10]. However,
several side effects such as rhabdomyolysis, liver and heart toxicity,
anemia and leukopenia as well as rodent liver carcinogenesis are
likely due to PPAR-independent mechanisms (rewieved in [11]). In
addition, despite observations that various PPARa ligands exert
a prosurvival action that was suggested to contribute to their
carcinogenic potential [12], some of them have been demonstrated
to induce apoptosis in different hepatoma cell lines.
An initial report from our laboratory [13] showed, quite
unexpectedly at the time, that treatment with CF promptly
induces massive and typical apoptosis in hepatoma cells of both rat
(Yoshida AH-130) and human (HepG2) origin, with no correlation
with the species-specificity of hepatocarcinogenesis. Subsequently,
similar observations were made on various cell lines exposed to CF
or other PPARa ligands such as nafenopin, perfluorooctanoic
acid, and BR931 [14,15,16]. Noterworthily, PPARa ligand
cytotoxicity is not restricted to cells of the hepatocytic lineage,
but it has also been observed in breast or lung cancer cell lines
[17,18] as well as in human keratinocytes and lymphoblasts
[19,20]. Furthermore, ligands of the other two PPAR isotypes, i.e.
b/d, and c, have been shown to induce cell death as well
[21,22,23], and CF itself can bind to all three PPAR subfamilies
[24].
Of particular interest are several reports that suggest the
potential use of PPARa ligands as antineoplastic drugs. In this
connection, a good insight into cell death mechanisms triggered by
these ligands becomes especially important. Previous results
obtained in our laboratory suggested that a role may be played
PLOS ONE | www.plosone.org 1 September 2012 | Volume 7 | Issue 9 | e45327
by inhibition of HMG-CoA reductase (HMGR), a key enzyme in
isoprenoid biosynthesis. Indeed, the mRNA level and enzymatic
activity of HGMR as well as the cholesterol content in
mitochondria are reduced in Yoshida AH-130 cells soon after
CF treatment, while cell death can be attenuated by supplement-
ing cells with mevalonate, the reaction product of HMGR [25].
Quite recently we also demonstrated [26] that the rapid apoptosis
induced by CF in the AH130 hepatoma cells is amenable to
a classic caspase-dependent intrinsic pathway.
The possibility that CF, and fibrate derivatives in general, in
addition to the hypolipidemic action, could be exploited also in
view of their cytotoxic activity is an interesting one. Indeed, these
drugs are currently used in the clinical practice and their side-
effects are generally compatible with a good quality of life. In this
regard, their possible use in combination with classical antineo-
plastic treatments is intriguing. The data actually available in the
literature are scanty and confusing, showing that CF may be
cytotoxic for several tumor cell lines, with poor attention given to
the underlying mechanisms. On this line, the present study tries to
fill this gap, investigating CF-induced apoptosis in Jurkat cells,
a human neoplastic line of hematopoietic origin. The results show
that CF quickly activates the apoptotic machinery through a non
conventional pathway that at least involves the initiator caspase 2,
likely activated via ER stress, and the effector caspase 3, though
not caspases 8 and 9.
Materials and Methods
All materials were supplied by Sigma (St. Louis, MO, USA),
unless differently specified.
Jurkat cells (from human leukemic transformed T lymphoma,
clone E6-1) were purchased from ATCC (Manassas, VA, USA),
seeded in RPMI 1640 medium supplemented with 10% fetal calf
serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-
glutamine, and maintained at 37uC in a humidified atmosphere of
5% CO2 in air. CF, dissolved in DMSO, was added to the
medium at the final concentration of 1 mM (or as specified).
Controls were treated with the solvent alone. In some experiments
Jurkat cells were pretreated with one of the following molecules:
zVAD-fmk (zVAD, 1 h, 20 mM), DEVD-cho (DEVD, 1 h,
20 mM), VDVAD-cho (VDVAD, 1 h, 20 mM) LEHD-cho
(LEHD, 1 h, 20 mM), IETD-cho (IETD, 1 h, 20 mM) from Alexis
Biochemicals (Lausen, Switzerland), cyclosporine A (CsA, 15 min,
1 mM), calpeptin (1 h, 250 mM), bapta-AM (1h, 10 mM) from
Biomol (Plymouth Meeting, PA, USA), SP600125 (1 h, 20 mM),
PD150606 (1 h, 20 mM), form Calbiochem (La Jolla, Ca, USA)
and EGTA (2mM, 30 min).
Flow Cytometry
DNA distribution analysis was performed as described else-
where [26]. Briefly, cells were washed in PBS, fixed in ice-cold
Figure 1. Kinetic of clofibrate-induced death in Jurkat cells. Morphological appearance (A: phase contrast microscopy, B: DAPI staining) of
Jurkat cells exposed to clofibrate (CF) 1 mM for 45 min (Co: control). (C) percentages of cells with hypodiploid DNA content (apoptotic; see Penna et
al., 2009) after exposure to CF (concentration on top of the bars, time on X axis). Data are expressed as mean 6 SD (n = 3). ** p,0,01 vs Co; ***
p,0,001 vs Co.
doi:10.1371/journal.pone.0045327.g001
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70% ethanol for at least 30 min, incubated at room temperature in
PBS containing DNase-free RNase (Type II-A) and propidium
iodide at the final concentrations of 0.4 mg/ml and 10 mg/ml,
respectively. Cells were then analyzed with a FACScan flow
cytometer (Becton & Dickinson, Mountain View, CA, USA)
equipped with a 488 nm argon laser and three filters, respectively
transmitting at 530 nm (FL1), 585 nm (FL2) and above 620 nm
(FL3). Data were analysed with the CellQuest software (Becton &
Dickinson). The percentage of apoptotic events has been assessed
by evaluating the accumulation of cells characterized by a ,2n
DNA fluorescence.
Mitochondrial depolarization was detected on unfixed cells
measuring the fluorescence emission shift of the lipophilic cationic
probe 5,5-6,6-tetra-chloro-1,1-3,3-tetraethylbenzimidazolyl-carbo-
cyanine iodide (JC-1, Molecular Probes, Invitrogen Corporation,
Carlsbad, CA, USA). JC-1 exhibits potential-dependent accumu-
lation in mitochondria, indicated by a fluorescence emission shift
from green (529 nm) to red (590 nm). The loss of mitochondrial
membrane potential is indicated by a decreased ratio between red
and green fluorescence [27].
Intracellular Ca2+ fluctuations were measured using the calcium
indicator OregonGreen488-Bapta1-AM (Molecular Probes, Invi-
trogen Corporation, Carlsbad, CA, USA). Briefly, cells (2?106)
were loaded with the specific calcium probe (2 mM, 30 min, room
temperature) in complete medium without phenol red, centrifuged
(600 g, 5 min) and resuspended in 1 ml of the same medium. Data
capture was performed recording the FL1 mean on 10,000 cells
for each time point. CF and/or A23187 were added after reading
the baseline fluorescence.
Caspase Activities
Cells were resuspended in 20 mM HEPES-KOH, pH 7.5,
containing 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 1 mM PMSF, frozen and thawed, sonicated,
centrifuged (14,000 g, 15 min, 4uC), and the supernatant collected.
Aliquots corresponding to 20 mg protein were diluted in caspase
buffer (25 mM HEPES, pH 7.5, 0.1% CHAPS, 10% sucrose,
10 mM DTT) and assayed for caspase 2, 3, 8, and 9 activities by
1 h incubation at 37uC in the presence of 20 mM substrates
Figure 2. Mitochondrial involvement in clofibrate-induced apoptosis. Shift of the FL2 (590 nm)/FL1 (529 nm; green to red) fluorescence
ratio of JC-1 in cells treated with clofibrate (CF) for 5 min (A: control (C); B: CF). (C) representative western blot showing the time course of Smac/
DIABLO and cytochrome c appearance in the cytosolic fraction (surnatant, SN). Cytochrome c oxidase subunit IV (COX4) serves as loading control for
mitochondrial enriched fraction (insoluble, INS) and actin for cytosolic fraction. (D) western blotting pattern representative of cyclosporine A and
zVAD pretreatment on cytochrome c release in cells exposed to CF for 30 min.
doi:10.1371/journal.pone.0045327.g002
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(VDVAD-AMC (AMC:7-amino-4-methylcoumarin)), DEVD-
AMC, IETD-AMC, LEHD-AMC; Biomol, Plymouth Meeting,
PA, USA). The reaction was stopped with 0.1% trichloroacetic
acid, and the fluorescence read in a Perkin-Elmer fluorometer
(excitation 380 nm – emission 460 nm). Free AMC was used as
working standard.
Western Blotting
Cells were suspended in 0.25% sodium deoxycholate and
homogenized by sonication. For cytochrome c detection, cells
were suspended in 20 mM HEPES-KOH, pH 7.2, containing
250 mM sucrose, 1 mM EDTA, 0.025% digitonin and freshly
added 0.1 mM PMSF, then centrifuged (14,000 g, 30 min, 4uC) to
obtain the mitochondrial (pellet) and the cytosolic (supernatant)
fractions.
Protein concentration was determined by the method of Lowry
et al. (1952), using BSA as working standard. Equal amounts of
protein (30 mg) were heat-denaturated in sample-loading buffer
(50 mM TRIS-HCl, pH 6.8, 100 mM DTT, 2% SDS, 0.1%
bromophenol blue, 10% glycerol), resolved by SDS-PAGE and
transferred for 2 h to nitrocellulose membranes (Bio-Rad,
Hercules, CA, USA). Protein transfer was checked by Ponceau S
staining. The filters were then blocked with Tris-buffered saline
(TBS) containing 0.05% Tween and 5% non-fat dry milk, and
incubated overnight with the following primary antibodies: Smac/
DIABLO, poly-ADP-ribose polymerase (PARP), caspase 2,
caspase 3, caspase 12, fodrin, JNK (Santa Cruz Biotechnology,
Santa Cruz, CA, USA); cytochrome c oxidase subunit IV (COX4),
p-eIF2a, eIF2a, p-JNK (Cell Signaling, Danvers, MA, USA);
cytochrome c (Becton & Dickinson, Mountain View, CA, USA);
actin and tubulin (Sigma, St. Louis, MO, USA). Peroxidase-
conjugated IgG (Bio-Rad, Hercules, CA, USA) was used as
secondary antibody. The membrane-bound immune complexes
were detected by an enhanced chemiluminescence system (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) on a photon-sensitive
film (Hyperfilm ECL; GE Healthcare, Milano, Italy). Bands were
quantified by densitometric scanning of the films and elaborated as
described in ‘Data analysis and presentation’.
Caspase-2 Silencing
The shRNA lentiviral vector pLKO.1,-puro bearing the
hairpin sequence CCGGGTTGAGCTGTGACTAC-
GACTTCTCGAGAAGTCGTAGTCACAGCT-
CAACTTTTTG was transfected in packaging HEK 293T cells
using calcium phosphate. 24 hours later, the supernatant contain-
ing the lentiviral particles was filtered (0,22 mm) and 1 ml added to
106 Jurkat cells. Infected cells were selected adding puromycin
1mg/ml during 2 weeks, tested for silencing efficiency and used for
subsequent experiments.
Data Analysis and Presentation
Results are expressed as means6 standard deviation (SD). Each
experiment was performed in triplicate or repeated three times.
Image quantification was obtained by densitometry and bands
Figure 3. Caspase activation in clofibrate-treated cells. (A) Kinetic of caspase enzymatic activity evaluated by measuring the cleavage of
specific fluorogenic substrates. Data are expressed as fold increase respect to control. (B) representative western blotting patterns of caspase and
PARP (poly-ADP-ribose polymerase) expression in CF-treated Jurkat cells. Tubulin serves as loading control. (C) Caspase 3 enzymatic activity in cells
pretreated with the indicated inhibitors before CF (clofibrate; grey bars) exposure for 30 min. Data (means6 SD, n= 3) are expressed as fold increase
respect to Co (control; black bar); ** p,0,01 vs Co; *** p,0,001 vs Co; 1 p,0,05 vs CF; 11 p,0,01 vs CF; 111 p,0,001 vs CF.
doi:10.1371/journal.pone.0045327.g003
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analyzed using a specific software (TotalLab, NonLinear Dynam-
ics, Newcastle upon Tyne, UK). Significance of the differences was
evaluated by the Student’s ‘t’ test.
Supplemental Material
Primary T cells were isolated using buffy coats from healthy
individuals (kindly supplied by CeRMS, Centro Ricerche
Medicina Sperimentale, Torino, Italy). PBMCs were separated
using the Ficoll-Paque reagent (GE Healthcare, Milano, Italy)
following the manufacturer’s instruction. Pan T cells were
obtained by negative selection retaining the non-target cells in
the magnetic field of a MACS Column (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany) after incubation with a cocktail of
biotin-conjugated monoclonal anti-human antibodies against
CD14, CD15, CD16, CD19, CD34, CD36, CD56, CD123, and
CD235a. The extracted cells were rapidly seeded in complete
medium (same as Jurkat cells) and immediately exposed to CF for
cytotoxicity assays.
Results
When exposed to 1 mM CF for 45 min, the standard treatment
schedule adopted throughout the present work, approximately
50% of Jurkat cells develop a frankly apoptotic morphology
characterized by cell shrinkage due to nuclear and cytoplasmic
condensation with nuclear fragmentation (Fig. 1A–B). Compara-
ble effects have been observed on different cell lines, such as
human HL-60 promyelocytic leukemia (Fig. S1A) or human
CCRF-CEM acute lymphoblastic leukemia (data not shwn), and
the murine Colon-26 carcinoma cells (Fig. S1B). Noteworthily,
a time/dose study shows that apoptosis is also induced by CF at
concentrations lower than 1 mM (Fig. 1C), even if propagating
more slowly in the cell population. These concentrations are well
within the usual therapeutic (antilipidemic) range that approx-
imates 0.5 mM in patient blood [28]. More pertinently, in
pharmacological terms, optimal therapeutic plasma levels of CF
have been reported to be around 0.5 mM ([28]; MICROMEDEX
Healthcare Series, POISINDEX Managements, Clofibrate and
related agents, www.thomsonhc.com). To verify if clofibrate exerts
Figure 4. Effect of different caspase inhibitors and caspase 2 silencing on apoptotic death in cells exposed to clofibrate. (A) cells were
pretreated with the indicated inhibitors, exposed to clofibrate (CF) and analysed after 45 min. Histograms refer to percentages of cells with
hypodiploid DNA content (black bars: untreated; grey bars: CF-treated). (B) sh-RNA effectively abrogates caspase 2 expression in Jurkat cells.
Co = control, Scr = scramble shRNA, shCSP2= caspase 2-specific shRNA; Lane 1: molecular weight marker. Tubulin is used as loading control. (C) flow-
cytometric analysis showing the percentages of cells with hypodiploid DNA content of the above mentioned cells exposed to 1 mM clofibrate for
45 min. Data are expressed as mean 6 SD (n = 3). ** p,0,01 vs Co; *** p,0,001 vs Co; 11 p,0,01 vs CF; 111 p,0,001 vs CF.
doi:10.1371/journal.pone.0045327.g004
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its cytotoxic activity also on normal cells, primary T lymphocytes
were exposed to the drug. The results shown in Fig. S2A
demonstrate that 45 minutes exposure to 1 mM clofibrate slightly
modifies the precentage of hypodiploid cells observed in control
cultures. The results do not change when T cells are stimulated
with anti-CD3 antibodies for 36 h, in order to have them in
a proliferative condition (% of hypodiploid cells: C= 11, CF=13).
In contrast to what observed in Jurkat cells (Fig. 1C), exposure of
T lymphocytes to low CF concentrations (0.5 mM) for a period
longer than the standard experimental schedule (from 459 to 8 h)
markedly delays the onset of cell death, leading to slightly
increased percentage of hypodiploid cells only after 8 h treatment
(Fig. S2B).
Mitochondrial Alterations Induced by CF
A drop in the mitochondrial membrane potential (Fig. 2A–B) as
well as a substantial release of cytochrome c to the cytosol (Fig. 2C)
manifest rapidly and are already remarkable after a 5 min
exposure of Jurkat cells to CF. By contrast, Smac/Diablo is barely
detectable in the cytosol (Fig. 2C). The release of cytochrome c to
the cytosol is clearly attenuated when the opening of the
permeability transition pore is inhibited with cyclosporine A
(Fig. 2D) or when cells are pretreated with the polycaspase
inhibitor zVAD (Fig. 2D). The latter finding indicates that
cytochrome c release is, at least in part, an effect rather then
a cause of a proteolytic event inhibited by zVAD.
CF-induced Death is Caspase-dependent
In a next step, Jurkat cells have been assayed for the enzymatic
activity of an effector (3) and three initiator (2, 8 and 9) caspases.
As Fig. 3A illustrates, caspase 2-like activity rapidly increases in the
first time interval (15 min) and is maintained active afterwards.
Conversely, the increase of both caspase 8- and 9-like activities is
more evident in the late phases (30–45 min). Finally, the caspase 3-
like activity markedly increases in a virtually linear fashion over
the whole 45 min interval. Caspase 2 and 3 activation is confirmed
by western blotting analysis: the precursor isoforms progressively
decrease after exposure to CF, while processed (active) caspase 3
becomes detectable (Fig. 3B), in parallel with an early and
extensive cleavage of its endogenous substrate PARP (Fig. 3B).
Jurkat cells lack any detectable caspase 4 expression (our original
observation, not shown) as well as any caspase 12 activity, which is
a general property of human cells [29]. Incidentally, no change in
the level of procaspase 12-like immunoreactive protein occurs in
CF-treated Jurkat cells over the whole experimental time (Fig. 3B).
CF-induced caspase 3 activation is completely abrogated when
cells are pretreated with either polycaspase (zVAD) or caspase 3
(DEVD) inhibitors (Fig. 3C). Among the initiator caspases, only
caspase 2 inhibition with VDVAD partially prevents caspase 3
activation, while inhibitors of caspase 8 (IETD) or 9 (LEHD) are
ineffective.
As emerging from inhibitor tests, CF-induced cell death is
caspase-dependent (Fig. 4A). Cells treated with zVAD become
Figure 5. Phosphorylation of eIF2a and JNK activation in clofibrate-treated cells. (A) Representative western blottings of phosphorylated
eIF2a and JNK (46 and 54 kDa isoforms). (B) histograms refer to the densitometric analysis. Data are expressed as arbitrary units. (C) Cells were
pretreated with the JNK inhibitor SP600125, then exposed to clofibrate (CF) and analysed after 45min. Histograms refer to percentages of cells with
hypodiploid DNA content (black bars: untreated; grey bars: CF-treated). Data are expressed as mean6 SD (n = 3). ** p,0,01 vs Co; *** p,0,001 vs Co;
1 p,0,05 vs CF.
doi:10.1371/journal.pone.0045327.g005
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almost completely refractory to CF cytotoxicity. Caspase 2 and 3
inhibitors (respectively, VDVAD and DEVD) afford no more than
a partial protection, which becomes higher when they are used
concomitantly. Finally, inhibitors such as IETD (caspase 8) or
LEHD (caspase 9) do not rescue cells from apoptosis, which is
consistent with their inability to affect caspase 3 activation (Fig. 3B).
In keeping with this finding, cyclosporine A, which is known to
suppress mitochondrial membrane permeability transitions, af-
fords no protection from cell death (Fig. 4A). To clarify if caspase 2
activation is crucial to CF citotoxicity, its expression in Jurkat cells
was abrogated by means of shRNA (Fig. 4B). The lack of caspase 2
rendered Jurkat cells more, although not completely, resistant to
CF-induced apoptosis. Indeed, the percentage of hypodiploid cells
was more than 50% in wild-type cultures, and about 30% in
caspase 2-depleted cells (Fig. 4C).
CF Induces ER Stress
At present, caspase 2 is not univocally associated with a precise
cell death pathway, yet there is evidence that on ER stress it may
act upstream of mitochondria to promote cytochrome c release
[30,31]. Therefore, we assessed the occurrence of ER stress in CF-
treated Jurkat cells by examining the phosphorylation status of the
stress-activated SAPK/JNK (46 and 54 kDa isoforms) and of the
translation inhibitory factor eIF2a and in both cases observed its
progressive increase (Fig. 5A–B). Furthermore, apoptosis by CF is
partially prevented in cultures pretreated with the JNK inhibitor
SP600125, which suggests a role for JNK in this death process
(Fig. 5C).
CF-induced Apoptosis does not Rely on Calpain
Activation
ER stress is often associated with or elicited by Ca2+
mobilization from ER stores, which results in increased cytosolic
Ca2+ concentrations ([Ca2+]i) that may trigger activation of the
Ca2+-dependent calpain system [32]. A physiological substrate of
the latter is fodrin, a cortical cytoskeletal protein, whose
cleavage can thus denote an ongoing calpain activation [33]
and has implications for membrane blebbing and phosphati-
dylserine externalization during apoptosis [34]. In CF-treated
Jurkat cells, fodrin cleavage into a 150 kDa product is already
Figure 6. Fodrin cleavage and effect of calpain inhibition in clofibrate-treated cells. (A) Representative western blotting of fodrin cleavage
in clofibrate (CF)-exposed Jurkat cells in the presence or in the absence of zVAD and calpeptin. (B) Cells were pretreated with the calpain inhibitors
calpeptin or PD150606, then exposed to CF and analysed after 45min. Histograms refer to percentages of cells with hypodiploid DNA content (black
bars: untreated; grey bars: CF-treated). Data are expressed as mean 6 SD (n = 3). ** p,0,01 vs Co; *** p,0,001 vs Co; 111 p,0,001 vs CF.
doi:10.1371/journal.pone.0045327.g006
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prominent at 5 min and virtually complete at 15 min, while
a 120 kDa fragment appears after 30 min (Fig. 6A). The
120 kDa fragment is generated by caspase 3 only, whereas both
calpain and caspase 3 can cut a similar though not identical
150 kDa fragment [33]. We thus used appropriate inhibitors in
order to discriminate between the latter two possibilities. As
Fig. 6A illustrates, the 150 and 120 kDa products of fodrin
cleavage both nearly disappear in the presence of zVAD,
whereas the calpain inhibitor calpeptin affords no more than
a weak decrease of the 150 kDa fragment. In apparent contrast
with the latter finding, calpeptin markedly protects Jurkat cells
from death by CF, yet such protection in not provided at all by
another calpain inhibitor such as PD150606 (Fig. 6B). Alto-
gether, these observations suggest that calpains make no
significant contribution to CF-induced apoptosis in Jurkat cells.
Ca2+ Influx Prevents CF-induced Apoptosis
Finally, we tested the hypothesis that altered Ca2+ homeo-
stasis could be critical for CF cytotoxicity, even if not necessarily
through calpain activation. CF was previously shown [35] to
induce transient increases of the [Ca2+]i in Jurkat cells. The
relevance of such increase to CF-induced apoptosis was not
investigated, however. In the present work, neither intracellular
nor extracellular Ca2+ chelators, such as OG-BAPTA-AM and
EGTA, respectively, prevent CF-induced apoptosis (Fig. 7A). In
addition, the Ca2+ ionophore A23187 by itself exerts no
appreciable toxicity on Jurkat cells, at least over the 45 min
interval herewith adopted (Fig. 7A). This observation implyes
that any change of [Ca2+]i caused by CF or the Ca
2+ influx
induced by A23187 separately are well tolerated by these cells.
Surprisingly, however, CF cytotoxicity is fully antagonized by
A23187 and such protection is abrogated when cells are in the
presence of EGTA (Fig. 7A). Not only enforced Ca2+ influx is
required for cell survival, but also other CF effects such as
caspase 3 activation and cytochrome c release are reduced by
A23187 (Fig. 7C–D). In agreement with [35], we found CF to
induce an early increase of [Ca2+]i, peaking at 1 min and
followed by a progressive decline (Fig. 7B). A23187 causes
a prompt [Ca2+]i rise that is largely maintained till the end of
the assay. Finally, cotreatment with CF and A23187 results in
a complex pattern including an initial [Ca2+]i spike followed by
a decline to a suprabasal plateau and by an eventual rise to
Figure 7. Effect of Ca2+ influx on clofibrate-induced apoptosis. (A) Cells were pretreated with OG-Bapta-AM or EGTA, then exposed to
clofibrate (CF) and/or the Ca2+ ionophor A23187 (5 mM) and analysed after 45min. Data are expressed as mean 6 SD (n = 3). *** p,0,001 vs Co; 111
p,0,001 vs CF. Histograms refer to percentages of cells with hypodiploid DNA content (black bars: without CF; grey bars: CF-treated). (B) cells were
incubated with OG-Bapta1-AM and treated with CF and/or A23187. Intracellular calcium release was measured by the increase of 523 nM
fluorescence. (C) Caspase 3 enzymatic activity in cells treated with CF and/or A23187 for 30 min. Data (means 6 SD, n = 3) are expressed as fold
increase respect to control. * p,0,05 vs Co; ** p,0,01 vs Co; *** p,0,001 vs Co; 11 p,0,01 vs CF. (D) western blotting representative of the effect of
CF and/or A23187 for 30 min on cytochrome c release. Cytochrome c oxidase subunit IV (COX)4 serves as loading control for mitochondrial enriched
fraction (P) and actin for cytosolic fraction (SN).
doi:10.1371/journal.pone.0045327.g007
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levels close to those produced by A23187, but quite higher than
those caused by CF per se. These findings can be likely
accounted for by the notion [35] that in Jurkat cells CF
$0.5 mM, not only stimulates a transient [Ca2+]i increase, but
also inhibits the external Ca2+ influx. They also seem to support
the view that a [Ca2+]i rise neither plays a crucial role in CF-
induced apoptosis of Jurkat cells nor is adequate to support
calpain activation and fodrin clevage, as shown above.
Discussion
In recent years, we have been investigating what initially
appeared as an unexpected property of CF, namely, its ability to
elicit a fast and extensive apoptotic process in cell lines of
neoplastic origin, particularly hepatocarcinomas [13,19,25,26],
among which the rat Yoshida ascites hepatoma AH-130 provided
the main paradigm. The observation that an important lethal
action is exerted by CF as well as other PPs on cells of both rodent
and human origin prompted us to evaluate carefully these agents
for their possible use as antineoplastic drugs. We noticed that
human T-lymphoma Jurkat cells are as susceptible as rat
hepatoma AH-130 cells to CF-induced apoptosis. This finding
suggests that CF could be useful in the treatment of lymphoid
malignancies. In this regard, to resort therapies less aggressive in
terms of systemic toxicity and side effects would represent a major
advance.
Mechanisms of CF-induced Apoptosis
Among PPAR ligands, only few studies have investigated the
cytotoxic mechanisms of those targeting PPARa. Among the
latter, some have been reported to activate apoptotic death in
various cell lines (reviewed by [36]). In our experience, PPARa
activation is unlikely to play any significant role in CF-induced
apoptosis of Jurkat (this report) or hepatoma cells, particularly in
view of its very rapid time-course [25]. All the potentially relevant
parameters herewith evaluated in Jurkat cells are already altered
within 5 min exposure to CF, and [Ca2+]i within 1 min.
Therefore, this fast apoptotic death should be likely categorized
as an extrareceptor activity, not differently from other effects of
PPARa ligands, such as ER or oxidative stress [12].
In both human Jurkat T-leukemia cells and rat AH-130
hepatoma cells [13,19,25,26] CF-induced apoptosis is caspase-
dependent, yet the two death processes follow different courses. As
previously found, caspases 3, 8, and 9 are rapidly activated in AH-
130 cells exposed to CF and relevant caspase inhibitors afford
a significant protection from apoptosis [26]. At variance, we
presently found that caspases 8 and 9 activation in Jurkat cells is
delayed, particularly with respect to caspase 3 and, in less striking
manner, to caspase 2. Moreover, while the mitochondrial pathway
appears to play a significant role in CF-treated AH-130 cells [26],
in Jurkat cells the pattern is quite different. Briefly, the
mitochondrial membrane potential rapidly falls and cytochrome
c is released in both cell lines, once exposed to CF, but Smac-
Diablo is released from mitochondria in AH-130 cells only
(unpublished data). Moreover, caspase-9 inhibition or treatment
with cyclosporine A are completely ineffective in protecting Jurkat
cells from death. Altogether, these observations suggest that the
mithocondrial pathway only marginally contributes to CF-induced
apoptosis of Jurkat cells.
The occurrence of ER stress in Jurkat cells exposed to CF is
documented by the early and marked increased phosphorylation
of two typical targets, eIF2a and JNK. Moreover, a selective JNK
inhibitor (SP600125) affords a partial protection from CF-induced
apoptosis, suggesting a role for JNK activation in this death. In last
years, ER stress has been proposed to trigger apoptosis through
mechanisms involving either caspase 12 [37] or 4 or 2, apart from
other initiator (8, 9) and effector (3, 7) caspases [38]. Since we
ruled out an involvement of both caspases 12 and 4 (see Results),
our attention was focused onto caspase 2, which is regarded as an
initiator caspase [39]. Dimerization and autocleavage of the p51
caspase 2 precursor lead to formation of an active p37 complex
that is subsequently cleaved by an unknown caspase into an
inactive 19 kDa fragment [39]. In the present study, the p51
precursor is already decreased in Jurkat cells after 5 min on CF,
indicating early activation of caspase 2 that subsequently further
increase through the whole experimental time. Of interest, the
inactive p19 fragment becomes detectable after 30 min on CF
(data not shown), suggesting that a late inhibitory cleavage might
maintain constant levels of active caspase 2.
Interestingly, CF has been reported to cause retrograde
movement of Golgi constituents to the ER and, independently
from PPARa activation, to disrupt the morphological and
functional integrity of the Golgi complex in a manner similar to
brefeldin A [40,41]. In conclusion, these observations are
compatible with the hypothesis that activation of Golgi- or ER-
associated caspase 2 are involved in the activation of caspase 3 in
CF-treated cells.
Role of Intracellular [Ca2+] in CF Cytotoxicity
Both ER stress and mitochondrial depolarization may result in
increases of cytosolic [Ca2+] i, which should be expected to
activate calpains. The latter in turn can be involved in the early
phases of apoptosis, leading to cleavage of the effector caspase 3
[42,43,44]. As an example, coincubation of Jurkat cells with
Entamoeba histolytica results in calpain-dependent caspase 3 activa-
tion and apoptosis, that can be prevented by calpeptin [45].
However, the involvement of calpain activation in CF-induced cell
death appears unlikely, in view of two different observations: (i)
even if calpeptin partially protects Jurkat cells from CF, this effect
probably relies on non-specific caspase inhibition, since calpeptin
only barely attenuates the intracellular fodrin cleavage if compared
to the polycaspase inhibitor zVAD; (ii) no significant protection
from CF is afforded by PD150606, another calpain inhibitor. A
[Ca2+]i rise can result either in pro- or antiapoptotic effects [46].
In the present work, a [Ca2+]i elevation occurs after CF, yet
treatments aimed at inhibiting it by means of extra- or intracellular
chelators confer no protection against CF-induced cell death. By
contrast, Ca2+ influx elicited by A23187 unexpectedly exerts
a marked antiapoptotic action in CF-treated Jurkat cells, this
protection being abrogated by adding EGTA into the medium.
Therefore, protection by A23187 appears to depend on its ability
to increase the Ca2+ influx in CF-treated cells, where it also
inhibits both cytochrome c release and caspase 3 activation. The
present data match a previous report of an antiapoptotic action of
Ca2+ influx in puromycin-treated U937 cells [46]. The negligible
toxicity of A23187 itself on Jurkat cells remains to be clarified.
Noteworthily, T-cells tolerate high [Ca2+]i as required for
activation, proliferation, and cytokine synthesis (reviewed by
[47]), nor death occurs in B-lymphoma cell cultures exposed to
anoxia/reoxygenation, in spite of a sustained [Ca2+]i rise [48].
Conclusion
The present study demonstrates that exposing Jurkat cells to CF
triggers a caspase-dependent apoptotic process not conforming to
a canonical pathway, wherein caspases 2, likely activated by ER
stress, and caspase 3 are involved. Finally, both apoptosis and
caspase 3 activation are prevented by Ca2+ influx, suggesting that
mobilization of Ca2+ stores from the ER combined with
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suppression of Ca2+ influx are as well a crucial event in the
pathway to cell death.
The present work on Jurkat cells significantly improves the
knowledge concerning PPARa ligand toxicity on tumor-derived
cell lines. So far, the data in the literature are relatively scanty and
quite scattered in terms of cell types and drugs investigated,
treatment schedule, and kinetic of the events under study. Two
groups of neoplastic cell lines received the largest share of attention
so far: those belonging to the hepatocytic lineage (see Introduction)
and those of hematopoietic origin. Among the latter, evidence for
growth arrest, induced differentiation and apoptosis driven by
PPARa ligands, alone or combined with other drugs, has been
obtained on neoplastic human cells of both lymphoid ([49], [50],
[20]) and myeloid origin ([51,52,53,54], [55]). On this basis, we
can at least conclude that remarkable antiblastic properties are
exhibited by a variety of PPARa ligands. In particular, clinically
relevant concentrations of CF exert a strong apoptogenic action on
human T-leukemia Jurkat cells, comparable with that on rat
hepatoma Yoshida AH-130 cells. Therefore, the present results
suggest that CF, a PPAR agonist that has been widely used in the
clinical handling of hyperlipemias, is worth being further
scrutinized as a potential low-toxicity and low-cost drug for
leukemia therapy. Further work on this issue is thus advisable.
Supporting Information
Figure S1 Clofibrate-induced apoptosis in HL-60 and
C26 cells. Representative plots of flow-cytometric analysis (see
Materials and Methods for details). Panel A: HL-60 cells, panel B:
C26 colon adenocarcinoma cells. M1 represents the percentage of
cells with hypodiploid DNA content (apoptotic).
(TIF)
Figure S2 Effect of clofibrate on primary T lympho-
cytes. Representative plots of flow-cytometric analysis (see
Materials and Methods for details), M1 represents the percentage
of cells with hypodiploid DNA content (apoptotic). Panel A: T cells
exposed to 1 mM CF for 45 min; Panel B: T lymphocytes exposed
to 0.5 mM clofibrate at different time points (from 45 min to 8 h).
(TIF)
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